Research map: Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy

Back to the article

Papers in this map

  1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer · Leora Horn · 2018 · 3642 citations · Cited by this paper
  2. Sarcosine-Based Pharmacokinetic Optimization and Fluorescent Dye Library Evaluation of Dual-Labeled PSMA Inhibitors for Fluorescence-Guided Surgery · 2026 · Related
  3. Comprehensive genomic profiles of small cell lung cancer · Julie George · 2015 · 2447 citations · Cited by this paper
  4. Antibody–Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors · 2026 · Related
  5. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial · Luis G Paz-Ares · 2019 · 2314 citations · Cited by this paper
  6. Fucoidan Ameliorates Contrast-Induced Acute Kidney Injury in Mice by Modulating the TLR4/NF-κB and Nrf2/GPX4 Pathways · 2026 · Related
  7. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges · Dai Fukumura · 2018 · 2048 citations · Cited by this paper
  8. Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound–Indication Matching and Precision Neurotherapeutic Development · 2026 · Related
  9. Small-cell lung cancer · Charles M. Rudin · 2021 · 1631 citations · Cited by this paper
  10. Potential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study · 2026 · Related
  11. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data · Charles M. Rudin · 2019 · 1339 citations · Cited by this paper
  12. Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK · 2026 · Related
  13. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities · Carl Michael Gay · 2021 · 990 citations · Cited by this paper
  14. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial · 2026 · Related
  15. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer · Triparna Sen · 2019 · 915 citations · Cited by this paper
  16. False Novelty in Antibacterial Natural-Product Discovery: Rediscovery, Structural Misassignment, and a Checkpoint Framework for Early Verification · 2026 · Related
  17. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial · Jonathan Wade Goldman · 2020 · 708 citations · Cited by this paper
  18. Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis · 2026 · Related
  19. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer · Marion M. Nau · 1985 · 673 citations · Cited by this paper
  20. Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances · 2026 · Related
  21. Small cell lung cancer: Where do we go from here? · Lauren A. Byers · 2014 · 651 citations · Cited by this paper
  22. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition · Gürkan Mollaoglu · 2017 · 620 citations · Cited by this paper
  23. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo · Laura R. Saunders · 2015 · 606 citations · Cited by this paper
  24. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy · Élodie Picarda · 2016 · 602 citations · Cited by this paper
  25. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1 · Lauren A. Byers · 2012 · 581 citations · Cited by this paper
  26. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study · Charles M. Rudin · 2016 · 579 citations · Cited by this paper
  27. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate · Abbie S. Ireland · 2020 · 556 citations · Cited by this paper
  28. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis · Eric E. Gardner · 2017 · 546 citations · Cited by this paper
  29. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization · Marina K. Baine · 2020 · 532 citations · Cited by this paper
  30. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC · Helai P. Mohammad · 2015 · 521 citations · Cited by this paper
  31. Unravelling the biology of SCLC: implications for therapy · Joshua K. Sabari · 2017 · 521 citations · Cited by this paper
  32. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial · José Manuel Trigo · 2020 · 488 citations · Cited by this paper
  33. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer · Maria Catherine Pietanza · 2018 · 408 citations · Cited by this paper
  34. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer · Benjamin Hoyin Lok · 2016 · 345 citations · Cited by this paper
  35. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study · Fiona Helen Blackhall · 2021 · 280 citations · Cited by this paper
  36. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy · Giannis Mountzios · 2025 · 272 citations · Cited by this paper
  37. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition · Arnaud Augert · 2019 · 250 citations · Cited by this paper
  38. Targeting the ATR-CHK1 Axis in Cancer Therapy · Stuart Rundle · 2017 · 235 citations · Cited by this paper
  39. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer · Catherine Allison Stewart · 2017 · 232 citations · Cited by this paper

Source: OpenAlex (CC0)